微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 55.57% | -9.58% | 1.5% | 62/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 54.75% | -9.9% | -8.48% | 65/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 59.82% | 15.99% | -6.72% | 51/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 64.13% | 9.18% | 4.35% | 44/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 61.46% | 3.65% | 1.14% | 47/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 60.77% | -0.66% | 17.82% | 50/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 51.57% | -9.4% | -12.19% | 73/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 58.74% | 5.85% | -0.94% | 59/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 59.29% | 0.65% | -3.07% | 57/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 61.17% | -1.02% | 7.46% | 55/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 56.93% | -4.95% | 2.59% | 61/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 55.49% | -17.15% | -5.8% | 72/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.91% | -11.38% | -4.68% | 58/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 61.8% | -9.82% | 3.18% | 56/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 59.89% | -14.05% | -10.58% | 58/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 66.98% | -3.81% | 0.76% | 49/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 66.47% | -6.57% | -3% | 41/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 68.53% | -8.54% | -1.66% | 42/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 69.68% | -5.4% | 0.08% | 31/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 69.63% | -14.32% | -2.14% | 39/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 71.15% | -14.35% | -5.05% | 32/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 74.93% | -13.43% | 1.72% | 24/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 73.66% | -15.41% | -9.35% | 25/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 81.26% | -12.27% | -2.18% | 15/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 83.06% | -10.4% | -4.02% | 9/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 86.55% | -6.38% | -0.62% | 9/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 87.09% | -5.62% | -5.98% | 5/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 92.63% | 3.05% | -0.08% | 4/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 92.7% | 5.72% | 0.28% | 3/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 92.44% | 7.74% | 0.18% | 3/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 92.28% | 9.03% | 2.66% | 3/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 89.89% | 6.31% | 2.51% | 6/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 87.69% | 4.32% | 2.2% | 3/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 85.8% | 3.36% | 1.38% | 5/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 84.63% | 1.75% | 0.1% | 5/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 84.55% | -0.11% | 0.59% | 8/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 84.06% | -0.69% | 1.26% | 5/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 83.01% | 126.04% | -0.2% | 5/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 83.18% | 138.01% | -1.73% | 4/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 84.65% | 118.44% | 0.01% | 6/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 84.64% | 125.86% | 130.47% | 4/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 36.73% | 9.93% | 5.08% | 51/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 34.95% | 80.72% | -9.81% | 46/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |